Hims & Hers Health, Inc. (NYSE:HIMS) CEO Sells $2,750,209.28 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total value of $2,750,209.28. Following the completion of the transaction, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at $487,789.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Andrew Dudum also recently made the following trade(s):

• On Monday, August 5th, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The shares were sold at an average price of $16.47, for a total value of $3,110,985.36.
• On Wednesday, July 3rd, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.75, for a total value of $3,919,426.00.
• On Thursday, June 20th, Andrew Dudum sold 45,755 shares of Hims & Hers Health stock. The stock was sold at an average price of $22.97, for a total value of $1,050,992.35.

Hims & Hers Health Price Performance

NYSE:HIMS traded down $0.18 on Thursday, reaching $14.43. 3,819,610 shares of the company’s stock were exchanged, compared to its average volume of 7,802,388. Hims & Hers Health, Inc. has a 52 week low of $5.65 and a 52 week high of $25.74. The stock has a fifty day simple moving average of $18.60 and a 200-day simple moving average of $16.75. The firm has a market cap of $3.10 billion, a price-to-earnings ratio of -1,461.00 and a beta of 1.08.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The business had revenue of $315.65 million during the quarter, compared to the consensus estimate of $302.43 million. During the same period in the previous year, the firm posted ($0.03) earnings per share. The firm’s revenue for the quarter was up 51.8% on a year-over-year basis. As a group, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.22 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of HIMS. Nisa Investment Advisors LLC increased its holdings in shares of Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after acquiring an additional 1,603 shares in the last quarter. Quest Partners LLC grew its holdings in shares of Hims & Hers Health by 5,944.1% in the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after purchasing an additional 3,507 shares during the period. Van ECK Associates Corp acquired a new stake in Hims & Hers Health during the second quarter worth $111,000. Belpointe Asset Management LLC raised its stake in shares of Hims & Hers Health by 10.0% in the 4th quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock valued at $118,000 after acquiring an additional 1,205 shares during the period. Finally, Amalgamated Bank raised its stake in shares of Hims & Hers Health by 55.9% in the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after acquiring an additional 2,354 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on HIMS. Needham & Company LLC assumed coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective on the stock. Jefferies Financial Group raised their price target on shares of Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, June 27th. Bank of America raised their price objective on Hims & Hers Health from $22.00 to $26.00 and gave the stock a “buy” rating in a research note on Thursday, June 13th. Truist Financial raised their price objective on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, July 18th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research note on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.29.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.